| Name | Title | Contact Details |
|---|
Ambient Clinical Analytics is the creator of a software platform designed for data assimilation, communication and analytics. It is based on decision support tools initially deployed in the intensive care unit (ICU) or emergency department of hospitals. Our software consists of algorithms that mine data from electronic medical records (EMR). It then presents that data to the physicians and nurses so they may facilitate real-time clinical decision making and care delivery. These products are positioned as add on applications that are designed to easily integrate with the current major EMR providers. The highly fragmented global Healthcare IT and EMR market is expected to grow by 15% to $10 billion by 2015. Ambient believes there is a significant opportunity in this growing market to implement analytics based dashboard tools to reduce errors and improve efficiency. Our goal is supported by a $16 million CMS grant to deploy Ambient’s AWARE program in 3 hospitals starting September 2013. This software platform can be used in any data intensive hospital unit and is the perfect combination of “Big Data” and “Analytics”. Our analytical tools and suggested care checklists are unique to the current healthcare IT market. Ambient Clinical Analytics is supported financially by software license fees, SaaS, Cloud, and system integration revenue.
Block Buying Group is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Expressable is an online speech therapy platform that offers 1 on 1 virtual sessions with experienced speech therapists, personalized curriculum, and weekly homework assignments to help integrate practice throughout daily life.
Assessment Technologies Institute is a Stilwell, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.